These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30554943)

  • 41. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
    Baud MGJ; Lin-Shiao E; Cardote T; Tallant C; Pschibul A; Chan KH; Zengerle M; Garcia JR; Kwan TT; Ferguson FM; Ciulli A
    Science; 2014 Oct; 346(6209):638-641. PubMed ID: 25323695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
    Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
    Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
    Dittmann A; Werner T; Chung CW; Savitski MM; Fälth Savitski M; Grandi P; Hopf C; Lindon M; Neubauer G; Prinjha RK; Bantscheff M; Drewes G
    ACS Chem Biol; 2014 Feb; 9(2):495-502. PubMed ID: 24533473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy.
    De S; Sahu R; Palei S; Narayan Nanda L
    Bioorg Med Chem; 2024 Oct; 112():117875. PubMed ID: 39178586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
    Baud MG; Lin-Shiao E; Zengerle M; Tallant C; Ciulli A
    J Med Chem; 2016 Feb; 59(4):1492-500. PubMed ID: 26367539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
    Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
    Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
    Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
    Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
    Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.
    Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP
    Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of methyl isoxazoleazepines as inhibitors of BET.
    Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
    Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
    Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
    Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
    Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.
    Alghamdi S; Khan I; Beeravolu N; McKee C; Thibodeau B; Wilson G; Chaudhry GR
    Stem Cell Res Ther; 2016 Feb; 7():22. PubMed ID: 26830473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.
    Belkina AC; Nikolajczyk BS; Denis GV
    J Immunol; 2013 Apr; 190(7):3670-8. PubMed ID: 23420887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
    Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
    Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.